Aliases & Classifications for Paraplegia

MalaCards integrated aliases for Paraplegia:

Name: Paraplegia 12 74 20 44 15 17 71
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 20
Paraplegia, Lower 12

Classifications:



External Ids:

Disease Ontology 12 DOID:607
ICD9CM 34 344.1
MeSH 44 D010264
NCIt 50 C50687
SNOMED-CT 67 155031004
ICD10 32 G82.2
UMLS 71 C0030486

Summaries for Paraplegia

MalaCards based summary : Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 7, autosomal recessive and spastic paraplegia 11, autosomal recessive, and has symptoms including ophthalmoplegia, hemiplegia and paraparesis. An important gene associated with Paraplegia is SPAST (Spastin), and among its related pathways/superpathways is Endocytosis. The drugs Fenofibrate and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, prostate and skin, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 74 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

Related Diseases for Paraplegia

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1132)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 7, autosomal recessive 33.0 SPG7 SPG11
2 spastic paraplegia 11, autosomal recessive 33.0 ZFYVE26 SPG7 SPG11 SPAST AP5Z1
3 spastic paraplegia 20, autosomal recessive 33.0 ZFYVE26 SPG7 SPAST SPART NIPA1 ATL1
4 spastic paraplegia 49, autosomal recessive 32.9 ZFYVE26 SPG7 SPG11 DDHD1
5 spastic paraplegia, optic atrophy, and neuropathy 32.9 WASHC5 AP5Z1
6 spastic paraplegia 5a, autosomal recessive 32.9 ZFYVE26 SPG7 SPG11 SPAST KIF5A CYP7B1
7 spastic paraplegia 63, autosomal recessive 32.9 SPG7 SPG11 CYP7B1
8 spastic paraplegia 3, autosomal dominant 32.8 SPG7 SPG11 SPAST RTN2 REEP1 NIPA1
9 spastic paraplegia 54, autosomal recessive 32.8 SPG7 SPG11 REEP1 DDHD1 AP5Z1
10 spastic paraplegia 64, autosomal recessive 32.8 SPG7 SPG11 SPAST
11 spastic paraplegia 46, autosomal recessive 32.8 ZFYVE26 SPG7 SPG11 SPAST CYP7B1 AP5Z1
12 spastic paraplegia 56, autosomal recessive 32.8 ZFYVE26 SPG7 SPG11 DDHD1 AP5Z1
13 spastic paraplegia 28, autosomal recessive 32.8 SPG7 SPG11 REEP1 DDHD1 AP5Z1
14 spastic paraplegia 55, autosomal recessive 32.8 ZFYVE26 SPG7 SPG11 DDHD1
15 spastic paraplegia 35, autosomal recessive 32.8 ZFYVE26 WASHC5 SPG7 SPG11 REEP1 CYP7B1
16 spastic paraplegia 73, autosomal dominant 32.8 REEP1 DDHD1 ATL1
17 spastic paraplegia 75, autosomal recessive 32.8 SLC33A1 PLP1
18 spastic paraplegia 57, autosomal recessive 32.8 SPG11 REEP1 KIF5A KIF1A ERLIN2
19 spastic paraplegia 50, autosomal recessive 32.7 ZFYVE26 SPG7 SPG11 RTN2 AP5Z1
20 spastic paraplegia 43, autosomal recessive 32.7 SPG11 SPAST SLC33A1 ERLIN2 ATL1
21 mast syndrome 32.7 ZFYVE27 SPG11 SPART
22 spastic paraplegia 52, autosomal recessive 32.7 ZFYVE26 SPG11 RTN2 AP5Z1
23 spastic paraplegia 16, x-linked 32.7 WASHC5 SPG7 SPG11 SPAST SLC33A1
24 spastic paraplegia 61, autosomal recessive 32.7 ZFYVE26 SPG11 SPAST RTN2 REEP1 ATL1
25 spastic paraplegia 26, autosomal recessive 32.7 SPG7 SPG11 SPART SLC33A1 REEP1
26 spastic paraplegia 53, autosomal recessive 32.7 WASHC5 SLC33A1 RTN2 ATL1 AP5Z1
27 spastic paraplegia 41, autosomal dominant 32.7 SPAST KIF5A
28 spastic paraplegia 25, autosomal recessive 32.6 ZFYVE26 WASHC5 SLC33A1 REEP1
29 spastic paraplegia 19, autosomal dominant 32.6 ZFYVE26 WASHC5 SLC33A1
30 spastic paraplegia 45, autosomal recessive 32.6 SPG11 SPART
31 spastic paraplegia 48, autosomal recessive 32.6 ZFYVE26 WASHC5 SPG7 SPG11 SPAST RTN2
32 spastic paraplegia 29, autosomal dominant 32.6 ZFYVE26 WASHC5 SLC33A1
33 spastic paraplegia 32, autosomal recessive 32.6 WASHC5 SPG7 SPG11 SLC33A1
34 spastic paraplegia 34, x-linked 32.6 ZFYVE26 WASHC5 SLC33A1 REEP1
35 spastic paraplegia 14, autosomal recessive 32.6 SPG7 SPG11 SPAST SLC33A1 ATL1
36 spastic paraplegia 44, autosomal recessive 32.5 ZFYVE27 SPG11 SLC33A1 PLP1 ERLIN2 CYP7B1
37 spastic paraplegia 17, autosomal dominant 32.5 ZFYVE27 ZFYVE26 WASHC5 SPG11 SPAST SPART
38 spastic paraplegia 47, autosomal recessive 32.5 ZFYVE26 WASHC5 SPG7 SPG11 SPAST REEP1
39 spastic paraplegia 31, autosomal dominant 32.5 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG11 SPAST
40 hereditary spastic paraplegia 51 32.5 ZFYVE26 SPG7 SPG11 AP5Z1
41 spastic paraplegia 37, autosomal dominant 32.5 ZFYVE26 WASHC5 SLC33A1 REEP1 ERLIN2
42 spastic paraplegia 12, autosomal dominant 32.5 ZFYVE27 ZFYVE26 WASHC5 SPG11 SPAST RTN2
43 spastic paraplegia 18, autosomal recessive 32.5 ZFYVE26 WASHC5 SPG7 SPG11 REEP1 NIPA1
44 spastic paraplegia 39, autosomal recessive 32.4 ZFYVE26 WASHC5 SPG7 SPG11 SPAST SPART
45 spastic paraplegia 15, autosomal recessive 32.4 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG11 SPAST
46 hereditary spastic paraplegia 23 32.4 ZFYVE26 WASHC5 SPG11 SPART SLC33A1 CYP7B1
47 complex hereditary spastic paraplegia 32.3 SPG7 SPG11 NIPA1 CYP7B1
48 spastic paraplegia 2, x-linked 32.3 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG11 SPAST
49 spastic paraplegia 6, autosomal dominant 32.3 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG11 SPAST
50 spastic paraplegia 33, autosomal dominant 32.3 ZFYVE27 ZFYVE26 WASHC5 SPG11 SPAST SPART

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Multiple Sclerosis
Neurogenic Bladder Osteoporosis
Paralytic Ileus Prostate Cancer
Protein-Energy Malnutrition Spinal Cord Disease
Vascular Myelopathy

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to Paraplegia

Symptoms & Phenotypes for Paraplegia

UMLS symptoms related to Paraplegia:


ophthalmoplegia, hemiplegia, paraparesis, paraplegia, ataxic, monoparesis, paraplegia, cerebral, paraplegia, spinal, monoplegia of lower limb affecting unspecified side, paraplegia, flaccid

MGI Mouse Phenotypes related to Paraplegia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 AP5Z1 ATL1 HSPD1 KIF1A KIF5A PLP1
2 growth/size/body region MP:0005378 9.73 AP5Z1 DDHD1 HSPD1 KIF1A KIF5A PLP1
3 nervous system MP:0003631 9.4 AP5Z1 HSPD1 KIF1A KIF5A PLP1 REEP1

Drugs & Therapeutics for Paraplegia

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fenofibrate Approved Phase 2, Phase 3 49562-28-9 3339
2
Acetylcholine Approved, Investigational Phase 2, Phase 3 51-84-3 187
3
4-Aminopyridine Approved Phase 3 504-24-5 1727
4 Neurotransmitter Agents Phase 2, Phase 3
5 Cholinergic Agents Phase 2, Phase 3
6 Botulinum Toxins Phase 2, Phase 3
7 Potassium Channel Blockers Phase 3
8
Atorvastatin Approved Phase 2 134523-00-5 60823
9
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
10
Evolocumab Approved Phase 1, Phase 2 1256937-27-5
11
Resveratrol Investigational Phase 2 501-36-0 445154
12 Protective Agents Phase 2
13 Anti-Inflammatory Agents Phase 2
14 Cathartics Phase 2
15 Antioxidants Phase 2
16 Gastrointestinal Agents Phase 2
17 Analgesics, Non-Narcotic Phase 2
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
19 Anti-Inflammatory Agents, Non-Steroidal Phase 2
20 Platelet Aggregation Inhibitors Phase 2
21 Antirheumatic Agents Phase 2
22 Analgesics Phase 2
23 Laxatives Phase 2
24 Pharmaceutical Solutions Phase 2
25 Hemagglutinins Phase 2
26 abobotulinumtoxinA Phase 2
27 Botulinum Toxins, Type A Phase 2
28 incobotulinumtoxinA Phase 2
29 Hypolipidemic Agents Phase 1, Phase 2
30 Antimetabolites Phase 1, Phase 2
31 Lipid Regulating Agents Phase 1, Phase 2
32 Anticholesteremic Agents Phase 1, Phase 2
33
mometasone furoate Approved, Investigational, Vet_approved 83919-23-7
34 Orange Approved
35
Testosterone undecanoate Approved, Investigational 5949-44-0
36
Testosterone enanthate Approved 315-37-7 9416
37
Testosterone Approved, Investigational 58-22-0 6013
38
Methyltestosterone Approved 58-18-4 6010
39
Idebenone Approved, Investigational 58186-27-9
40
tannic acid Approved 1401-55-4
41
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
42
Metronidazole Approved 443-48-1 4173
43
Aspartic acid Approved, Nutraceutical 56-84-8 5960
44
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
45
Choline Approved, Nutraceutical 62-49-7 305
46 Hormones
47 Hormone Antagonists
48 Testosterone 17 beta-cypionate
49 Anabolic Agents
50 Antineoplastic Agents, Hormonal

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Activity-Dependent Plasticity After Spinal Cord Injury Unknown status NCT00059553 Phase 2, Phase 3
2 An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI Completed NCT02455336 Phase 2, Phase 3 Fenofibrate
3 Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study Completed NCT02604186 Phase 2, Phase 3
4 Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial Not yet recruiting NCT03899584 Phase 3 4-Aminopyridine;Placebo oral capsule
5 A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayedstart Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients Not yet recruiting NCT03935724 Phase 2, Phase 3
6 A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury Withdrawn NCT02053883 Phase 2, Phase 3 Cethrin (BA-210);Placebo
7 Randomised Open Study of the Efficiency and Tolerance of the Use of a Corset on the Respiratory Function of Spinal Cord Injury Patients Withdrawn NCT01569360 Phase 3
8 Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury Unknown status NCT02326662 Phase 1, Phase 2
9 Electrical Stimulation Induced Lower Limb Exercise Capacity, Cardiorespiratory Response, Cardiovascular Risk Factors and Muscle Activity Patterns in Response to Robotic Assisted Treadmill Gait Training in Individuals With Complete Motor Spinal Cord Injury Completed NCT01349478 Phase 1, Phase 2
10 A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury Completed NCT00500812 Phase 1, Phase 2 Cethrin
11 Design and Validation of a Modular Physiotherapy Concept for the Treatment of Hereditary Spastic Spinal Paralysis (HSP) - a Randomized Study Completed NCT03961906 Phase 2
12 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Completed NCT02314208 Phase 2 Xenbilox;Tahor
13 Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin) in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Completed NCT02188277 Phase 2 Xeomin;Botox®
14 PCSK9 Inhibitor Treatment for Patients With Hereditary Spastic Paraplegia Type 5 Recruiting NCT04101643 Phase 1, Phase 2 evolocumab
15 A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries Suspended NCT00073853 Phase 2
16 A Prospective, Randomised, Controlled, Open Study. Phase II Treatment Equivalent. Terminated NCT00429013 Phase 2
17 Rehabilitation of the Lower Extremity With AMES Following Incomplete Spinal Cord Injury (SCI) Terminated NCT01498991 Phase 1, Phase 2
18 The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI) Completed NCT01739023 Phase 1
19 Use of Interactive Gaming After Spinal Cord Injury Completed NCT01537978 Phase 1
20 Orthostatic Tolerance During FES-evoked Stepping in Paraplegia: A Safety and Viability Study Completed NCT00108043 Phase 1
21 The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation Completed NCT02354625 Phase 1
22 Improving Ambulatory Community Access After Paralysis Recruiting NCT01570816 Phase 1
23 The Development of Systems for Paraplegic Cycling: Improving Health After Spinal Cord Injury Unknown status NCT00204100
24 Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury Unknown status NCT01386762 Early Phase 1
25 Assessment of Home/Work Simulation Tasks and Community Mobility Skills in the ReWalk Powered Exoskeleton in Persons With Spinal Cord Injury Unknown status NCT02118194
26 Early Intervention to Reduce Bone Loss After Spinal Cord Injury Unknown status NCT02334410
27 NSC Assistive Technology Research: Reciprocating Gait Orthoses for Paraplegia Patients Unknown status NCT02227407
28 Computationally Quantifying Wheelchair Set-Up to Minimize Peak Shoulder Joint Forces Throughout Manual Wheelchair Propulsion: A Pilot Study Unknown status NCT00785278
29 Freehand Ultrasound to Evaluate Scapular Kinematics in People With Paraplegia Unknown status NCT02357914
30 Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias Unknown status NCT00140829
31 Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations Unknown status NCT00136630
32 A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection. Unknown status NCT03499366
33 A Randomized, Crossover Clinical Trial of Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI Unknown status NCT02314221
34 Body Composition Assessment in Spinal Cord Injury Unknown status NCT00957762
35 The ReWalk Exoskeletal Walking System for Persons With Paraplegia Completed NCT01454570
36 Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy Completed NCT01815814
37 A Hebbian Approach to Regaining Control of Spared Circuits in Spinal Cord Injury Completed NCT01740128
38 Effects of a Single Exercise Session or Meal on Physical and Mental Health of People With Spinal Cord Injury: a Case Series Study Completed NCT03955523
39 Spinal Cord Injury: Endurance, Strength and Cardiac Function Induced by Efficient Training Protocols Completed NCT00987155
40 Prosthetic Arthroplasties in Weight-bearing Shoulders in Individuals With Long-term Wheelchair Use Completed NCT04418050
41 Nebido® Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia Completed NCT00838838 Testosterone Undeconate (Nebido-R, BAY86-5037)
42 A Patient Centric Motor Neuron Disease Activities of Daily Living Scale Completed NCT02852278
43 Nuclear Magnetic Spectroscopy for the Evaluation of Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis Completed NCT00023075
44 A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Improvement of Gait in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Completed NCT03627416
45 Studying Cognition in SPG4 Compared to Healthy Controls Completed NCT03104088
46 Feasibility of Telephone Counseling to Increase Physical Fitness in SCI (Co-Motion Study) Completed NCT02225028
47 Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO) Completed NCT01251549
48 Cardiovascular Parameters for Lokomat Training in Chronic Incomplete SCI Completed NCT00385918
49 Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions Completed NCT01208584
50 Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia. Completed NCT02042508

Search NIH Clinical Center for Paraplegia

Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

Anatomical Context for Paraplegia

MalaCards organs/tissues related to Paraplegia:

40
Spinal Cord, Prostate, Skin, Bone Marrow, Bone, Thyroid, Cortex

Publications for Paraplegia

Articles related to Paraplegia:

(show top 50) (show all 12897)
# Title Authors PMID Year
1
Genotype-phenotype study and expansion of ARL6IP1-related complicated hereditary spastic paraplegia. 61
33188530 2021
2
Hereditary spastic paraplegia. 61
33439395 2021
3
Hereditary spastic paraplegia type 11: Clinicogenetic lessons from 339 patients. 61
33581793 2021
4
Acute Aortic Occlusion and Its Sequelae: Metabolic, Pathologic Etiology, and Management. 61
32349067 2021
5
Ventriculoperitoneal Shunt Malfunction, a Rare Cause of Paraplegia after Kyphosis Correction: A Case Report and Literature Review. 61
33156276 2021
6
Acute paraplegia as a presentation of acute aortic occlusion. 61
33384750 2021
7
Hereditary spastic paraplegia: An "ears of the lynx" magnetic resonance imaging sign in a patient with recessive genetic type 11. 61
32885726 2021
8
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial. 61
33595142 2021
9
A heterozygous mutation in the CCDC88C gene likely causes early-onset pure hereditary spastic paraplegia: a case report. 61
33602173 2021
10
Evidence for Non-Mendelian Inheritance in Spastic Paraplegia 7. 61
33598982 2021
11
Impact of the urgency and the landing zone on rates of in-hospital death, stroke, and paraplegia following thoracic endovascular aortic repair in Japan. 61
33548443 2021
12
Intra-arterial thrombolytic therapy for acute anterior spinal artery stroke. 61
33358345 2021
13
A Case of Miyazaki Syndrome Caused by Arachnoid Cyst-Peritoneal Shunt. 61
33257305 2021
14
Whole exome sequencing uncovered highly penetrant recessive mutations for a spectrum of rare genetic pediatric diseases in Bangladesh. 61
33594065 2021
15
[Vitamin D Deficiency in Sports]. 61
33530783 2021
16
Midterm outcomes in patients undergoing endovascular repair of thoracic aortic aneurysms and penetrating atherosclerotic ulcers using the RelayPlus stent graft. 61
32565108 2021
17
Ddhd1 knockout mouse as a model of locomotive and physiological abnormality in familial spastic paraplegia. 61
33600578 2021
18
Expanding the Spectrum of AP5Z1-Related Hereditary Spastic Paraplegia (HSP-SPG48): A Multicenter Study on a Rare Disease. 61
33543803 2021
19
A Nepalese family with an REEP2 mutation: clinical and genetic study. 61
33526816 2021
20
Results of cryopreserved arterial allograft replacement for thoracic and thoracoabdominal aortic infections. 61
33485491 2021
21
Surgical pathway proposal for severe paralytic scoliosis in adolescents with myelomeningocele. 61
33585957 2021
22
[Spinal cord vascular diseases]. 61
33599788 2021
23
Good association between sprint power and aerobic peak power during asynchronuous arm-crank exercise in people with spinal cord injury. 61
31184928 2021
24
Predictors of Self-Efficacy Among People With Spinal Cord Injury During Inpatient Rehabilitation: A Cross-Sectional Study. 61
33555118 2021
25
An isolated ruptured spinal aneurysm presents with a thalamic Infarct: case report. 61
33535981 2021
26
Clinical Outcome and Histological Findings After Induced Leakage of PMMA Loaded With Methotrexate and Cisplatin During Vertebroplasty: Experimental Model in Pigs. 61
33601909 2021
27
Olfactory ensheathing cells: Unique glial cells promising for treatments of spinal cord injury. 61
33605466 2021
28
Inception cohort of the Swiss Spinal Cord Injury cohort study (SwiSCI): Design, participant characteristics, response rates and non-response 61
33569608 2021
29
Neuraxial and peripheral misconnection events leading to wrong-route medication errors: a comprehensive literature review. 61
33144409 2021
30
A study of probable benefit of a bioresorbable polymer scaffold for safety and neurological recovery in patients with complete thoracic spinal cord injury: 6-month results from the INSPIRE study. 61
33545674 2021
31
Experimental near-infrared spectroscopy-guided minimally invasive segmental artery occlusion. 61
33538301 2021
32
Exome sequencing of a Pakistani family with spastic paraplegia identified an 18 bp deletion in the cytochrome B5 domain of FA2H. 61
33246395 2021
33
Spastic paraplegia as the only symptom in two adult-onset patients carrying a novel pathogenic variant in PYCR2. 61
32920934 2021
34
Sex, support and society: a journey to reclaiming sexuality for individuals living with paraplegia in Cape Town, South Africa. 61
33051560 2021
35
Effect of high-intensity interval training on cardiometabolic component risks in persons with paraplegia: protocol for a randomised controlled trial. 61
33600014 2021
36
A Single Bout of Upper-Body Exercise Has No Effect on Postprandial Metabolism in Persons with Chronic Paraplegia. 61
33560775 2021
37
Oxygen Uptake During Exoskeletal-Assisted Walking in Persons With Paraplegia. 61
33181116 2021
38
[Symptoms of paraplegia]. 61
33595676 2021
39
Risk factors for spinal cord injury and complications of cerebrospinal fluid drainage in patients undergoing fenestrated and branched endovascular aneurysm repair. 61
32640318 2021
40
Blended Phenotype of Silver-Russell Syndrome and SPG50 Caused by Maternal Isodisomy of Chromosome 7. 61
33553621 2021
41
Brain Damage and Gene Expression Across Hereditary Spastic Paraplegia Subtypes. 61
33576112 2021
42
Emergency surgical management of cervical spine fracture-dislocation with acute paraplegia in COVID-19 (Coronavirus disease 2019)-suspected patient: first experience from a German spine centre. 61
33095369 2021
43
Early outcomes associated with use of the Zenith TX2 Dissection Endovascular Graft for the treatment of Stanford type B aortic dissection. 61
33600932 2021
44
A novel REEP1 splicing mutation with broad clinical variability in a family with hereditary spastic paraplegia. 61
32905827 2021
45
Spastic Paraplegia with Paget's Disease of Bone due to a VCP Gene Mutation. 61
32893227 2021
46
Improving gait adaptability in patients with hereditary spastic paraplegia (Move-HSP): study protocol for a randomized controlled trial. 61
33413555 2021
47
Familiarity with Hereditary Spastic Paraplegia (HSP) and Differentiation of Upper Body Gait Characteristics between Children with HSP and Spastic Diplegic Cerebral Palsy. 61
32942942 2021
48
Intramural haematoma of the thoracic aorta: A case series. 61
33456776 2021
49
Celiac Plexus Block Complications: A Case Report and Review of the Literature. 61
33395560 2021
50
Novel variants in PNPLA6 causing syndromic retinal dystrophy. 61
33141049 2021

Variations for Paraplegia

Copy number variations for Paraplegia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 170541 3 155544315 155572167 Copy number SLC33A1 Paraplegias

Expression for Paraplegia

Search GEO for disease gene expression data for Paraplegia.

Pathways for Paraplegia

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.32 ZFYVE27 WASHC5 SPART KIF5A

GO Terms for Paraplegia

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.91 ZFYVE27 WASHC5 SPAST SLC33A1 RTN2 REEP1
2 endoplasmic reticulum membrane GO:0005789 9.76 ZFYVE27 SPAST SLC33A1 RTN2 REEP1 ERLIN2
3 axon cytoplasm GO:1904115 9.26 SPG7 SPAST KIF5A KIF1A
4 endoplasmic reticulum tubular network GO:0071782 8.92 ZFYVE27 SPAST REEP1 ATL1

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoskeleton-dependent intracellular transport GO:0030705 9.26 KIF5A KIF1A
2 synaptic vesicle transport GO:0048489 9.16 SPG11 KIF5A
3 retrograde neuronal dense core vesicle transport GO:1990049 8.96 KIF5A KIF1A
4 anterograde axonal transport GO:0008089 8.8 SPG7 SPAST KIF1A

Molecular functions related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.26 SPAST REEP1 KIF5A KIF1A
2 ATP-dependent microtubule motor activity, plus-end-directed GO:0008574 9.16 KIF5A KIF1A
3 ATPase activity GO:0016887 9.02 SPG7 SPAST KIF5A KIF1A HSPD1

Sources for Paraplegia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....